Incidence of Major Bleeding in Patients with Pulmonary Thromboembolism Treated with Fixed Dose Alteplase 100 mg.
Dae-Hwan BaeWon Jae LeeYoon Mi ShinPublished in: Journal of Korean medical science (2020)
The major bleeding risk was higher in our study (26.3%) than in a previously published meta-analysis (9.24%). Therefore, we suggest reducing the dose of alteplase in patients who are elderly, Asian, or have cardiovascular disease. Further prospective studies of efficacy and bleeding rate after low dose alteplase should be considered.
Keyphrases
- low dose
- cardiovascular disease
- systematic review
- atrial fibrillation
- acute ischemic stroke
- end stage renal disease
- newly diagnosed
- ejection fraction
- meta analyses
- chronic kidney disease
- type diabetes
- prognostic factors
- pulmonary hypertension
- risk factors
- high dose
- randomized controlled trial
- patient reported outcomes
- middle aged
- cardiovascular risk factors